Skip to content
The Policy VaultThe Policy Vault

Tagrisso — United Healthcare

Central Nervous System (CNS) Cancer

Initial criteria

  • Diagnosis of brain metastases from EGFR mutation-positive NSCLC OR Diagnosis of leptomeningeal metastases from EGFR mutation-positive NSCLC

Reauthorization criteria

  • Documentation of positive clinical response to Tagrisso therapy

Approval duration

12 months